Sun Pharma gets USFDA nod for eye inflammation drug
The company is likely to commercialise BromSite through its newly formed US-based division Sun Ophthalmics in the second half of 2016.
Apr 11, 2016, 08:23 AM IST
Sun Pharma makes tender offer to acquire InSite Vision
Drug major Sun Pharmaceutical Industries has made a tender offer to acquire US-based eyecare firm InSite Vision for USD 0.35 per share in cash.
Sep 29, 2015, 19:41 PM IST
Sun Pharma up over 2% on deal with US-based InSite Vision
Sun Pharma's stock gained over 2 percent Wednesday as the company has entered into an agreement with InSite Vision to acquire the US-based eyecare firm for around USD 48 million plus related debt and other transaction costs to strengthen its branded ophthalmic portfolio in the American market.
Sep 16, 2015, 18:03 PM IST
Sun Pharma seals deal to acquire US-based InSite Vision
Drug major Sun Pharmaceutical Industries has entered into an agreement with InSite Vision to acquire the US-based eyecare firm for around USD 48 million plus related debt and other transaction costs to strengthen its branded ophthalmic portfolio in the US.
Sep 16, 2015, 11:21 AM IST
